

July 21, 2026

To Shareholders,

Company Name: Renascience Inc.
Representative: Toshio Miyata, Chairman and CEO
(Code: 4889 TSE Growth)
For inquiries, please contact Administration Dept.

**Announcement of Initiation of a Phase I Clinical Trial at King Abdullah International Medical
Research Center (KAIMRC) in Saudi Arabia**

We are pleased to announce that we have entered into a Clinical Trial Agreement with King Abdullah International Medical Research Center (KAIMRC), a governmental medical research institution in the Kingdom of Saudi Arabia, to initiate a Phase I clinical trial of RS5614 in Saudi Arabia.

Background and Purpose of the Clinical Trial

On October 9, 2025, we announced the execution of a Memorandum of Understanding (MOU) with KAIMRC to collaborate on the clinical development of our PAI-1 inhibitor RS5614 in Saudi Arabia, including its application as a therapeutic agent for anti-aging/longevity as well as for joint research and future commercialization.

This clinical trial represents a concrete initiative under this agreement and marks the commencement of clinical evaluation of our investigational product in Saudi Arabia.

Outline of the Clinical Trial

This Phase I study will evaluate the safety and tolerability of the PAI-1 inhibitor RS5614, together with exploratory biological assessments.

- Study Title: Phase I Safety and Tolerability Study of RS5614 with Exploratory Biological Assessments
- Study Institution: KAIMRC (Saudi Arabia)
- Principal Investigator: Dr. Raneem Milyani (Consultant, Geriatric and Internal Medicine Director)
- Timeline: This study is expected to be completed by the end of December 2026, with the final report to be received thereafter.
- Costs: KAIMRC (Saudi Arabia)

Based on the results of this trial, we plan to conduct a Phase II trial to evaluate anti-aging benefits of RS5614.

Impact on Financial Results

At present, we believe that the impact of this matter on our financial results for the current fiscal year will be minimal. We will promptly disclose any material developments as they arise.